Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trasylol Public Health Advisory Cites Kidney, Heart Attack, Stroke Risks

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will convene an advisory committee meeting to discuss the risks and benefits of Bayer's transfusion-sparing agent following risk reports.

You may also be interested in...



New Labeling Limits Patient Population Of Bayer’s Trasylol

Changes are the result of September advisory committee meeting, concerns over renal dysfunction.

New Labeling Limits Patient Population Of Bayer’s Trasylol

Changes are the result of September advisory committee meeting, concerns over renal dysfunction.

Trasylol Clinical Benefit To Be Reviewed By FDA Advisory Committee

Cardiovascular & Renal Drugs Advisory Committee will also consider reports of hypersensitivity and renal and cardiovascular risk linked to Bayer’s aprotinin injection at its Sept. 21 meeting.

Related Content

Topics

UsernamePublicRestriction

Register

PS063802

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel